Skip to search formSkip to main contentSkip to account menu

regorafenib

Known as: 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, Regorafenibum 
An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular… 
National Institutes of Health

Related topics

Related topics

5 relations
NCIt Antineoplastic Agent TerminologyStivargaregorafenib 40 MG Oral Tablet [Stivarga]

Broader (2)

Phenylurea CompoundsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A Pilot Study of Apatinib as Third‐Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
2018
2018
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Background Although sorafenib-regorafenib sequential therapy improves the prognosis of patients with hepatocellular carcinoma… 
2018
2018
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practice
As second‐line therapy, regorafenib has been shown to provide a survival benefit for patients with hepatocellular carcinoma (HCC… 
2017
2017
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard… 
2016
2016
Involvement of Notch‐1 in Resistance to Regorafenib in Colon Cancer Cells
Regorafenib, an oral small‐molecule multi kinase inhibitor, is able to block Vascular Endothelial Growth Factor Receptors (VEGFR… 
Review
2014
Review
2014
Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
Review
2014
Review
2014
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Review
2013
Review
2013
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
Regorafenib is a novel multikinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced… 
2012
2012
EGFR mutations in circulating tumour DNA.
2012
2012
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)